UK CDMO Sterling Pharma Solutions acquires US facility

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/NicoElNino)
(Image: Getty/NicoElNino)

Related tags CDMO Sterling Pharma Solutions Manufacturing

With 70% of its customers in North America and demand increasing, the UK-based CDMO Sterling Pharma Solutions has acquired CiVentiChem’s US facility in Cary, North Carolina.

“Over the last two years we have seen an increasing demand for our services from customers in the US, as well as recognizing the huge potential for future growth in the North American market,”​ said Andrew Henderson, sales and marketing director at Sterling Pharma Solutions.

According to the contract development and manufacturing organization (CDMO) – which was acquired by GHO Capital earlier this year – the North American market makes up 70% of its customer portfolio.

“The decision to acquire was driven by this demand and our desire to be able to offer our customers access to a local team,”​ Henderson added.

The new facility is located close to the Research Triangle Park in North Carolina and will be able to cater to smaller volumes, Henderson said, “Adding the facility to our portfolio gives us a solid platform to pursue our business ambitions.”

Since 2016, Sterling has more than doubled its sales after a management buy-out, according to the CDMO. 

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers